Celrixafor

Celrixafor is a medication used to treat certain types of cancer, including multiple myeloma and non-Hodgkin’s lymphoma. It is a stem cell mobilizer that works by stimulating the release of stem cells from the bone marrow into the bloodstream, allowing for the collection of stem cells for transplantation. Here are some key points about the product:

Composition:

Celrixafor contains Plerixafor, a chemotherapy medication that is used to treat cancer.

Indications:

Celrixafor is indicated for the treatment of:

1. Multiple myeloma in patients who have previously received autologous stem cell transplantation
2. Non-Hodgkin’s lymphoma in patients who have previously received autologous stem cell transplantation

Mechanism of Action:

Plerixafor works by:

1. Inhibiting the binding of stem cell factor to its receptor, which increases the release of stem cells from the bone marrow
2. Stimulating the migration of stem cells from the bone marrow to the bloodstream

Dosage and Administration: The recommended dosage of Celrixafor is:

• 24mg administered as an intravenous injection over 2-5 minutes
• The dose may be repeated every 4 hours as needed, up to a maximum of 3 doses

Side Effects:

Common side effects of Celrixafor include:

1. Pain or discomfort at the injection site
2. Nausea and vomiting
3. Fatigue
4. Headache
5. Dizziness
6. Abdominal pain

Serious side effects can include:

1. Anaphylaxis (severe allergic reaction)
2. Hemolytic uremic syndrome (a rare but potentially life-threatening condition)
3. Bone marrow failure
4. Infections

Contraindications:

Celrixafor is contraindicated in patients with:

1. Hypersensitivity to Plerixafor
2. Severe renal impairment or end-stage renal disease
3. Severe liver disease or cirrhosis
4. Pregnancy or breastfeeding

Precautions:

1. Patients with a history of kidney disease or liver impairment should be closely monitored while receiving Celrixafor.
2. Patients with a history of bleeding disorders should be closely monitored while receiving Celrixafor.
3. Patients with a history of infections should be closely monitored while receiving Celrixafor.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of pain or discomfort at the injection site.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from moisture.
• Do not freeze or expose to direct sunlight.
• Use within 24 hours of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.